Janssen Presents Updated Results Evaluating Talquetamab (GPRC5DxCD3 Bispecific Antibody) in Heavily Pre-treated Patients with Multiple Myeloma
- EMEA Innovative Medicine
- Janssen Presents Updated Results Evaluating Talquetamab (GPRC5DxCD3 Bispecific Antibody) in Heavily Pre-treated Patients with Multiple Myeloma
Janssen Presents Updated Results Evaluating Talquetamab (GPRC5DxCD3 Bispecific Antibody) in Heavily Pre-treated Patients with Multiple Myeloma
- X (Twitter)
Copy link